Literature DB >> 34269951

Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean national health and nutrition examination survey (KNHANES).

A Lum Han1.   

Abstract

Osteoarthritis of the knee (knee OA) is on the rise due to the aging population and increasing obesity. In addition to mechanical stress attributed to weight and age, osteoarthritis is associated with obesity and metabolic dysregulation. Here, a cross-sectional study targeting retrospectively registered 17,476 adults aged 50 years or older who were enrolled in the National Health and Nutrition Survey (2010-2011) was performed to analyze the association between the newly named metabolic associated fatty liver disease (MAFLD) and knee OA. Fatty liver index (FLI) ≥ 60 confirmed the presence of MAFLD, and FLI < 30 indicated the absence of MAFLD. Knee OA was diagnosed according to the Kellgren-Lawrence scale based on knee radiography results. A complex sample logistic regression analysis was performed. Statistically significant factors were adjusted to estimate probability ratios, and 95% confidence intervals were used to investigate the association between knee OA and MAFLD. The probability of knee OA was 1.479 times higher in the presence of MAFLD than that in the normal group. The results indicate that MAFLD is significantly associated with knee OA, suggesting that these two disorders should be managed simultaneously.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Fatty liver index; Kellgren-Lawrence scale; Knee osteoarthritis; Metabolic associated fatty liver disease; Metabolic dysfunction; Obesity

Mesh:

Year:  2021        PMID: 34269951     DOI: 10.1007/s10787-021-00842-7

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  5 in total

1.  Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.

Authors:  Mohammed Eslam; Jacob George
Journal:  J Hepatol       Date:  2020-09-12       Impact factor: 25.083

2.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

3.  Genetic insight into COVID-19-related liver injury.

Authors:  Cristiana Bianco; Guido Baselli; Francesco Malvestiti; Luigi Santoro; Serena Pelusi; Maria Manunta; Giacomo Grasselli; Alessandra Bandera; Luigia Scudeller; Daniele Prati; Luca Valenti
Journal:  Liver Int       Date:  2020-11-03       Impact factor: 5.828

Review 4.  A metabolic aspect of osteoarthritis: lipid as a possible contributor to the pathogenesis of cartilage degradation.

Authors:  K Masuko; M Murata; N Suematsu; K Okamoto; K Yudoh; H Nakamura; T Kato
Journal:  Clin Exp Rheumatol       Date:  2009 Mar-Apr       Impact factor: 4.473

5.  Increased All-Cause Mortality Associated With Digoxin Therapy in Patients With Atrial Fibrillation: An Updated Meta-Analysis.

Authors:  Ying Chen; Xiaoyan Cai; Weijun Huang; Yanxian Wu; Yuli Huang; Yunzhao Hu
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.